Rotavirus specific maternal antibodies and immune response to RV3-BB rotavirus vaccine in central java and yogyakarta, Indonesia
Margie H Danchin, Julie E Bines, Emma Watts, Daniel Cowley, Daniel Pavlic, Katherine J Lee, Hamidul Huque, Carl Kirkwood, Hera Nirwati, Jarir At Thobari, Cahya Dewi Satria, Yati Soenarto, Vicka Oktaria
Vaccine | ELSEVIER SCI LTD | Published : 2020
BACKGROUND: Placental or breast milk maternal antibodies can potentially reduce oral rotavirus vaccine efficacy in developing countries. We aimed to examine the relationship between the level of rotavirus specific immunoglobulin A (IgA) and neutralising antibodies (NA) in colostrum and breast milk and cord IgG, with cumulative vaccine take following one and three doses of oral RV3-BB rotavirus vaccine within a Phase IIb trial in Indonesia. METHODS: 196 infants received three doses of RV3-BB in a randomized, double-blinded trial, using a neonatal schedule (first dose at 0-5 days of age, n = 61), an infant schedule (first dose at ~ 8 weeks of age, n = 67) or placebo (n = 68). Rotavirus specifi..View full abstract
This work was supported by grants from the Murdoch Childrens Research Institute, the Maurice and Phyllis Paykel Trust and the Shepard Foundation.